{"id":76,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2002-09-04","marketCap":132.63009643554688,"name":"Galectin Therapeutics Inc","phone":"16786203186.0","outstanding":59.58000183105469,"symbol":"GALT","website":"https://galectintherapeutics.com/","industry":"Biotechnology"},"price":2.115025,"year":2023,"month":10,"day":6,"weekday":"Friday","title":"Ownership Structure of Galectin Therapeutics Inc Stock","date":"2023-10-06","url":"/posts/2023/10/06/GALT","content":[{"section":"Institutional Investors","text":"1. Vanguard Group Inc: The Vanguard Group is the largest institutional investor in Galectin Therapeutics Inc, owning approximately 9.05% of the company's outstanding shares."},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""},{"section":"","text":""}],"tags":["stock","Long","Biotechnology"],"news":[{"category":"company","date":1696334400,"headline":"Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis","id":122928776,"image":"https://media.zenfs.com/en/globenewswire.com/089af21c6219080c2660263701842b67","symbol":"GALT","publisher":"Yahoo","summary":"NORCROSS, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its fourth data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with portal hypertension caused by non-alcoholic steatohepatitis (NASH) liver cirrhosis. NAVIGATE is the first study of its kind and is a global effort that randomize","url":"https://finance.yahoo.com/news/galectin-therapeutics-reports-positive-outcome-120000244.html"},{"category":"company","date":1696317180,"headline":"Galectin Therapeutics reports DSMB concludes NAVIGATE can continue as designed","id":122931963,"image":"","symbol":"GALT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3143403414"},{"category":"company","date":1695729600,"headline":"Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023","id":122776218,"image":"https://media.zenfs.com/en/globenewswire.com/089af21c6219080c2660263701842b67","symbol":"GALT","publisher":"Yahoo","summary":"NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced it will participate in the 20th edition of the Discovery on Target meeting, the industry’s preeminent event on Novel Drug Targets and Technologies. The Company will present an update on its belapectin liver cirrhosis program during the Fibrosis and Inflammation session. The presentation, titled “Targeting Activated Macrophages","url":"https://finance.yahoo.com/news/galectin-therapeutics-present-belapectin-liver-120000470.html"},{"category":"company","date":1695713040,"headline":"Galectin Therapeutics to present update on belapectin liver cirrhosis program","id":122791581,"image":"","symbol":"GALT","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3133362564"},{"category":"company","date":1695527460,"headline":"More Personal Portfolio: Biotech, Commodities, And Gold","id":122752925,"image":"","symbol":"GALT","publisher":"TalkMarkets","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3130806606"}]}